Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$80.45 USD

80.45
2,626,827

-0.71 (-0.88%)

Updated Sep 11, 2024 03:11 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Top Ranked Income Stocks to Buy for April 17th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 17th

Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

by Zacks Equity Research

Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

by Kinjel Shah

Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

Swarup Gupta headshot

Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall

by Swarup Gupta

The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.

Alkermes Reports Positive Data From Schizophrenia Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?

by Zacks Equity Research

J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.

AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer

by Zacks Equity Research

AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.

PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

by Zacks Equity Research

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

by Zacks Equity Research

Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

Kinjel Shah headshot

Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

by Kinjel Shah

Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

Kinjel Shah headshot

Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

by Kinjel Shah

Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

Will Ironwood Suffer From Dependence on Linzess' Progress?

by Zacks Equity Research

Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

Kinjel Shah headshot

Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

by Kinjel Shah

Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck

by Zacks Equity Research

The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.

Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up

by Zacks Equity Research

Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.

Clovis Posts Data on Rubraca Study for Pancreatic Cancer

by Zacks Equity Research

Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.

Merck's Keytruda Gets Nod for First-Line Lung Cancer in China

by Zacks Equity Research

Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.

Advaxis Up on Positive Early-Stage Immunotherapy Study Data

by Zacks Equity Research

Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.

AstraZeneca's Selumetinib Gets Breakthrough Therapy Status

by Zacks Equity Research

AstraZeneca's (AZN) MEK 1/2 inhibitor, selumetinib gets Breakthrough Therapy designation for the treatment of paediatric patients with inoperable NF1-related PN.

AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA

by Zacks Equity Research

AVEO Pharmaceuticals (AVEO) focuses on the NDA for Fotivda in the United States for the treatment of advanced or metastatic RCC.

Kinjel Shah headshot

AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo

by Kinjel Shah

AstraZeneca (AZN) signs a collaboration deal, potentially costing $6.9 billion, with Japan's Daiichi Sankyo to develop/commercialize a promising cancer treatment.

Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals

by Zacks Equity Research

AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.

AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

Calithera (CALA) Initiates Phase I/II Study of Telaglenastat

by Zacks Equity Research

Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.